Technical Data
I7661-75C
Interferon alpha 2 (alpha 2b), Recombinant, Human (Interferon alpha-2, IFN-alpha-2, IFNa2, IFNa2b, Interferon alpha-A, IFN-alphaA, IFNA, LeIF A, MGC125764, MGC125765)
100ug
Molecular Biology Storage: -20CShipping: Blue Ice
Recombinant protein corresponding to 165aa of human Interferon-alpha 2b expressed in E.coli is a single, non-glycosylated, polypeptide chain.

Biological Activity:
The specific activity as determined in a viral resistance assay using bovine kidney MDBK cells was found to be 2.6x10e8 IU/mg.

Protein Content:
Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 0.924 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of Recombinant corresponding to Interferon-alpha 2b as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months after receipt at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 3 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~19.3kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol 2005 Jul;40(7):722-32. 2. Treatment of early pterygium recurrence with topical administration of interferon alpha-2b. Can J Ophthalmol 2005 Apr;40(2):185-7. 3. p53 protein expression in chronic hepatitis C; effect of interferon alpha 2b therapy. Hepatogastroenterology 2005 Jul-Aug;52(64):1176-9. 4. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005 Jul;12(4):380-5. 5. Safety and efficacy of an indigenous recombinant interferon-alpha-2b in patients with chronic myelogenous leukaemia: results of a multicentre trial from India. Natl Med J India 2005 Mar-Apr;18(2):66-70. 6. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. Dig Dis Sci 2005 May;50(5):970-5.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.